WO2007076371A3 - Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same - Google Patents

Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same Download PDF

Info

Publication number
WO2007076371A3
WO2007076371A3 PCT/US2006/062328 US2006062328W WO2007076371A3 WO 2007076371 A3 WO2007076371 A3 WO 2007076371A3 US 2006062328 W US2006062328 W US 2006062328W WO 2007076371 A3 WO2007076371 A3 WO 2007076371A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
core carrier
delivery
making
methods
Prior art date
Application number
PCT/US2006/062328
Other languages
French (fr)
Other versions
WO2007076371A2 (en
Inventor
Gerardo M Castillo
Elijah M Bolotin
Original Assignee
Pharmain Corp
Gerardo M Castillo
Elijah M Bolotin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmain Corp, Gerardo M Castillo, Elijah M Bolotin filed Critical Pharmain Corp
Priority to KR1020087017728A priority Critical patent/KR101529318B1/en
Priority to EP18194631.0A priority patent/EP3449946A3/en
Priority to AU2006330610A priority patent/AU2006330610B2/en
Priority to KR1020157030760A priority patent/KR20150125732A/en
Priority to CN2006800521271A priority patent/CN101365490B/en
Priority to KR1020147017736A priority patent/KR101872061B1/en
Priority to JP2008547735A priority patent/JP2009520040A/en
Priority to CA2633070A priority patent/CA2633070C/en
Priority to EP06846696.0A priority patent/EP1971372B1/en
Publication of WO2007076371A2 publication Critical patent/WO2007076371A2/en
Publication of WO2007076371A3 publication Critical patent/WO2007076371A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.
PCT/US2006/062328 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same WO2007076371A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020087017728A KR101529318B1 (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP18194631.0A EP3449946A3 (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
AU2006330610A AU2006330610B2 (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
KR1020157030760A KR20150125732A (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
CN2006800521271A CN101365490B (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
KR1020147017736A KR101872061B1 (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2008547735A JP2009520040A (en) 2005-12-19 2006-12-19 Hydrophobic core carrier composition for delivery of therapeutic agents and methods of making and using the same
CA2633070A CA2633070C (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP06846696.0A EP1971372B1 (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81362905P 2005-12-19 2005-12-19
US60/813,629 2005-12-19

Publications (2)

Publication Number Publication Date
WO2007076371A2 WO2007076371A2 (en) 2007-07-05
WO2007076371A3 true WO2007076371A3 (en) 2008-01-17

Family

ID=38218806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/062328 WO2007076371A2 (en) 2005-12-19 2006-12-19 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Country Status (8)

Country Link
US (3) US20070141145A1 (en)
EP (2) EP1971372B1 (en)
JP (4) JP2009520040A (en)
KR (3) KR101529318B1 (en)
CN (1) CN101365490B (en)
AU (1) AU2006330610B2 (en)
CA (1) CA2633070C (en)
WO (1) WO2007076371A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US8562998B2 (en) 2008-10-12 2013-10-22 President And Fellows Of Harvard College Targeting of antigen presenting cells with immunonanotherapeutics
US8637028B2 (en) 2008-10-12 2014-01-28 President And Fellows Of Harvard College Adjuvant incorporation in immunonanotherapeutics
US8906381B2 (en) 2008-10-12 2014-12-09 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
AU2003219922B2 (en) * 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
JP2009520040A (en) 2005-12-19 2009-05-21 ファーマイン コーポレーション Hydrophobic core carrier composition for delivery of therapeutic agents and methods of making and using the same
US20100297023A1 (en) * 2006-12-22 2010-11-25 Imuthes Limited University Of The Witwatersrand Lipid
EP2173168A1 (en) * 2007-06-11 2010-04-14 BioCure, Inc. Vesicles for active macromolecule delivery
EP2167103B1 (en) * 2007-07-19 2017-03-01 Allexcel, Inc. Self-assembling amphiphilic polymers as anticancer agents
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2197454A4 (en) * 2007-09-25 2012-07-04 Idexx Lab Inc Pharmaceutical compositions for administering oligonucleotides
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
EP2279414A4 (en) * 2008-04-21 2011-06-29 Merck Sharp & Dohme Pancreatic beta-cell mass biomarker
KR101078302B1 (en) * 2008-05-29 2011-10-31 (주)프로넥스 Drug Delivery System
WO2010028217A1 (en) * 2008-09-05 2010-03-11 The Board Of Trustees Of The University Of Illinois Poly(ethylene glycol) methyl ether carbodiimide coupling reagents for the biological and chemical functionalization of water soluble nanoparticles
ES2734884T3 (en) * 2009-09-09 2019-12-12 Pharmain Corp Anionic core composition for the delivery of therapeutic agents and methods of preparation and use thereof
US20110135704A1 (en) * 2009-12-08 2011-06-09 Shipp John I Infection Control for Surgical and Trauma Patients
CN101829338A (en) * 2010-04-23 2010-09-15 武汉理工大学 Novel amphiphilic macromolecular prodrug based on thiopurine medicine and preparation method thereof
ES2731678T3 (en) * 2013-07-31 2019-11-18 Pharnext Diagnostic tools for Alzheimer's disease
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
KR101665176B1 (en) * 2014-04-24 2016-10-13 영남대학교 산학협력단 Pharmaceutical composition for promoting growth
CN107106658B (en) * 2014-10-27 2021-07-09 久光制药株式会社 Microneedle device containing gene recombinant follicle stimulating hormone
BR112017009308B1 (en) 2014-11-03 2021-11-03 Pharmain Corporation GRAFT COPOLYMER EXCIPIENT PRODUCTION METHOD WITH A SUPERIOR PROTEIN AND PEPTIDE BINDING PROPERTY, AND COMPOSITION
WO2016210098A1 (en) 2015-06-24 2016-12-29 Board Of Regents, The University Of Texas System Dual assembly nanoparticles
US11077135B2 (en) 2015-08-14 2021-08-03 Synedgen, Inc. Derivatized chitosan polymers and methods of treating vascular disorders
BR112019003898A2 (en) * 2016-08-30 2019-05-21 Particle Sciences, Inc. composition and use of composition
CN106620677B (en) * 2017-02-06 2020-05-08 北京大学第一医院 Urokinase preparation based on high-molecular carrier and preparation method thereof
WO2019049862A1 (en) * 2017-09-05 2019-03-14 味の素株式会社 Polylysine derivative
KR20190127277A (en) * 2018-05-04 2019-11-13 주식회사 삼양바이오팜 Polymeric nanoparticle composition for delivering mRNA and preparation method thereof
WO2021207349A1 (en) * 2020-04-07 2021-10-14 Joseph Habboushe Prevention and treatment of virial infections
CN111467499A (en) * 2020-04-18 2020-07-31 中山市君泽科技有限公司 Graphene-loaded combined cancer treatment method
CN116546982A (en) * 2020-05-24 2023-08-04 李兆阳 Retinoic acid compositions and methods thereof
EP4165067A2 (en) * 2020-06-12 2023-04-19 Pharmain Corporation C-type natriuretic peptides and methods thereof in treating acute lung injury
WO2022005593A1 (en) * 2020-07-02 2022-01-06 Purdue Research Foundation Inhalation formulations of antimicrobial compounds
CN112358492B (en) * 2020-11-13 2022-04-15 兰州大学 Carboborane celecoxib, preparation thereof and application thereof in boron neutron capture treatment medicine for head and neck cancer
CN112402625B (en) * 2020-11-19 2022-12-09 健进制药有限公司 Photosensitizer-loaded PEG (polyethylene glycol) heparin nano micelle and preparation method thereof
CN112618481B (en) * 2021-02-22 2021-11-09 山东第一医科大学附属省立医院(山东省立医院) Modified hydrogel, modified hydrogel microspheres and preparation method and application thereof
CN113444250B (en) * 2021-06-18 2022-10-25 绍兴文理学院附属医院 Polyglycerol fatty acid ester derivative containing polyglutamic acid group, synthetic method thereof and application thereof in pharmaceutical preparation
CN114042148B (en) * 2022-01-13 2022-04-15 浙江湃肽生物有限公司深圳分公司 Etecatide hydrochloride stabilizer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381446B1 (en) * 1989-01-31 1994-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal compositions
WO2004014451A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
US20060233857A1 (en) * 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
JPH07503943A (en) * 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド Cross-linked polysaccharides, polycations and lipids useful for encapsulation and drug release
US5770563A (en) 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
EP1236473A3 (en) * 1992-04-03 2003-01-15 The Regents Of The University Of California Self-assembling polynucleotide delivery system
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
EP0665729B1 (en) * 1992-09-04 2003-05-07 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
MX9504664A (en) * 1994-03-07 1997-05-31 Dow Chemical Co Bioactive and/or targeted dendrimer conjugates.
US5466467A (en) 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
WO1996041818A1 (en) * 1995-06-09 1996-12-27 Drohan William N Chitin hydrogels, methods of their production and use
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
WO1997014740A1 (en) 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
US5683387A (en) * 1996-01-29 1997-11-04 Garito; Jon C. Electrosurgical electrode for skin grafting
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (en) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
JP2001510151A (en) * 1997-07-18 2001-07-31 インファイムド，インク． Biodegradable macromers for controlled release of bioactive substances
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
CA2339326A1 (en) 1998-08-10 2000-02-24 Josephine Egan Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
ATE355827T1 (en) * 1998-08-12 2007-03-15 Yissum Res Dev Co LIPOSOMAL THERAPEUTIC COMPOSITIONS PRODUCED BY AMMONIUM SULFATE GRADIENT
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
BR0008590A (en) * 1999-01-08 2001-10-30 Emisphere Tech Inc Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed
US6365173B1 (en) * 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
JP4812167B2 (en) * 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド Drug transport matrix and methods for making and using the same
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
KR20030009389A (en) * 2000-03-14 2003-01-29 브루카드 괴케 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
KR100518046B1 (en) * 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Treatment of acute coronary syndrome with glp-1
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US7807780B2 (en) 2000-07-21 2010-10-05 Revance Therapeutics, Inc. Multi-component biological transport systems
US20040092432A1 (en) * 2000-08-24 2004-05-13 Thomas Jefferson University Peptide compositions with effects on cerebral health
US6521736B2 (en) 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
US6894024B2 (en) * 2000-10-20 2005-05-17 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
WO2002048192A2 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
MXPA03005135A (en) * 2000-12-13 2003-12-04 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides.
JP4775985B2 (en) * 2000-12-27 2011-09-21 三井化学株式会社 Polymer and production method thereof
EP1351742B1 (en) * 2001-01-12 2008-10-15 Waratah Pharmaceuticals Inc. Compositions for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands
JP2005506956A (en) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー Long-acting GLP-1 formulation
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
US6586524B2 (en) * 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
MXPA04001525A (en) * 2001-08-23 2004-05-31 Lilly Co Eli Glucagon-like peptide-1 analogs.
BR0212620A (en) 2001-10-01 2005-09-20 Lilly Co Eli Methods of treating critically ill patients suffering from respiratory distress, and critically ill patients having a condition causing respiratory distress, and use of a glp-1 compound
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
JP4124734B2 (en) 2001-11-26 2008-07-23 アスビオファーマ株式会社 Nasal absorption pharmaceutical composition
RU2332229C2 (en) 2002-02-20 2008-08-27 Эмисфире Текнолоджис Инк. Method of glp-1 molecules introduction
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
AU2003219922B2 (en) * 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
AU2003243929B2 (en) 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
JP2006501820A (en) 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン Modified GLP-1 receptor agonists and their pharmacological uses
GB0221941D0 (en) 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
CN1767815A (en) 2003-03-31 2006-05-03 阿尔萨公司 Non-aqueous single phase vehicles and formulations utilizing such vehicles
ES2425221T3 (en) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc New methods and compositions for enhanced transmucosal delivery of peptides and proteins
ATE529126T1 (en) 2003-06-03 2011-11-15 Novo Nordisk As STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS
ES2380437T3 (en) 2003-06-03 2012-05-11 Novo Nordisk A/S GLP-1 peptide stabilized pharmaceutical compositions
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
TWI353250B (en) 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
AU2005251676B2 (en) 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
FR2867679B1 (en) 2004-03-17 2008-08-22 Oreal COSMETIC COMPOSITION COMPRISING MODIFIED POLYAMINES AND USES THEREOF.
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
KR100843362B1 (en) 2004-04-20 2008-07-02 덴드리틱 나노테크놀로지즈, 인크. Dendritic polymers with enhanced amplification and interior functionality
US20060134166A1 (en) 2004-05-25 2006-06-22 Luthra Ajay K Absorbable biocompatible materials
EP1768692B8 (en) * 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
RU2393168C2 (en) 2004-07-19 2010-06-27 Биокон Лимитед Insulin-oligomer conjugates, preparations and use thereof
US20090202497A1 (en) 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
WO2007030706A1 (en) 2005-09-08 2007-03-15 New England Medical Center Hospitals, Inc. Fragments of the glucagon-like peptide-i and uses thereof
JP2009509700A (en) 2005-10-05 2009-03-12 エスセーアー・ハイジーン・プロダクツ・アーベー Absorbent article comprising a hydrophilic region and a hydrophobic region
ES2625109T3 (en) 2005-10-25 2017-07-18 Starpharma Pty Limited Macromolecular compounds that have controlled stoichiometry
PT1965823T (en) 2005-11-04 2016-08-18 Glaxosmithkline Llc Methods for administering hypoglycemic agents
JP2009520040A (en) 2005-12-19 2009-05-21 ファーマイン コーポレーション Hydrophobic core carrier composition for delivery of therapeutic agents and methods of making and using the same
CN104524596B (en) 2006-01-20 2018-10-09 星药股份有限公司 Modified macromolecular
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381446B1 (en) * 1989-01-31 1994-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal compositions
WO2004014451A1 (en) * 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
US20060233857A1 (en) * 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1971372A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9539210B2 (en) 2007-10-12 2017-01-10 Massachusetts Institute Of Technology Vaccine nanotechnology
US9526702B2 (en) 2007-10-12 2016-12-27 Massachusetts Institute Of Technology Vaccine nanotechnology
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics
US9308280B2 (en) 2008-10-12 2016-04-12 Massachusetts Institute Of Technology Targeting of antigen presenting cells with immunonanotherapeutics
US9439859B2 (en) 2008-10-12 2016-09-13 Massachusetts Institute Of Technology Adjuvant incorporation in immunoanotherapeutics
US9233072B2 (en) 2008-10-12 2016-01-12 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8906381B2 (en) 2008-10-12 2014-12-09 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
US8637028B2 (en) 2008-10-12 2014-01-28 President And Fellows Of Harvard College Adjuvant incorporation in immunonanotherapeutics
US8562998B2 (en) 2008-10-12 2013-10-22 President And Fellows Of Harvard College Targeting of antigen presenting cells with immunonanotherapeutics

Also Published As

Publication number Publication date
EP3449946A3 (en) 2020-11-04
JP2016074744A (en) 2016-05-12
EP3449946A2 (en) 2019-03-06
KR101529318B1 (en) 2015-06-16
US10507248B2 (en) 2019-12-17
JP2013177408A (en) 2013-09-09
WO2007076371A2 (en) 2007-07-05
KR20080092923A (en) 2008-10-16
AU2006330610A1 (en) 2007-07-05
CN101365490B (en) 2012-11-28
CA2633070A1 (en) 2007-07-05
EP1971372B1 (en) 2018-11-14
US20140154203A1 (en) 2014-06-05
US9737615B2 (en) 2017-08-22
JP6148062B2 (en) 2017-06-14
KR101872061B1 (en) 2018-06-27
JP2009520040A (en) 2009-05-21
US20170368190A1 (en) 2017-12-28
KR20140093292A (en) 2014-07-25
CA2633070C (en) 2016-03-08
CN101365490A (en) 2009-02-11
AU2006330610B2 (en) 2012-08-16
US20070141145A1 (en) 2007-06-21
KR20150125732A (en) 2015-11-09
EP1971372A2 (en) 2008-09-24
EP1971372A4 (en) 2013-05-29
JP2014132036A (en) 2014-07-17

Similar Documents

Publication Publication Date Title
WO2007076371A3 (en) Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
WO2008034124A3 (en) Targeted polymeric prodrugs containing multifunctional linkers
WO2006125082A3 (en) Hydrogels and hydrogel particles
WO2008033300A8 (en) Bis (thiohydrazide amides) formulation
WO2008106129A3 (en) Polymeric micelles for combination drug delivery
WO2009036368A3 (en) Drug carriers
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
WO2007134290A8 (en) Implant and delivery system with multiple marker interlocks
MX2010001219A (en) Tunably crosslinked hyaluronic acid compositions.
PL1940905T3 (en) Preparations containing hyperbranched polymers
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2011062965A8 (en) Targeting monomers and polymers having targeting blocks
WO2007042554A3 (en) Methods and compositions for treating immune disorders
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
UA91575C2 (en) Four branched dendrimer-peg for conjugation to proteins and peptides
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
WO2003011226A3 (en) Products and drug delivery vehicles
EP2298074A3 (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
JO2721B1 (en) Artemisinin Derivative Dimers, Their preparation and their therapeutic application
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
WO2004004598A3 (en) Polymerized and modified rapamycins and their use in coating medical prostheses
WO2008109432A3 (en) Therapeutic targeting of interleukins using sirna in neutral liposomes
WO2003028696A8 (en) Compositions for delivery of drug combinations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2633070

Country of ref document: CA

Ref document number: 5068/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008547735

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006846696

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006330610

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087017728

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006330610

Country of ref document: AU

Date of ref document: 20061219

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200680052127.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020147017736

Country of ref document: KR